- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05802797
Bioavailability and Pharmacodynamics of EPA and DHA From Fortified Soymilk and Capsules
January 22, 2024 updated by: Yael Vodovotz, Ohio State University Comprehensive Cancer Center
Bioavailability and Pharmacodynamics of Eicosapentaenoic Acid and Docosahexaenoic Acid in Soymilk and Commercial Supplements
This study will compare the algae oil fortified soymilk to a commercial algae oil capsule containing the same base oil with the goal of demonstrating equivalent or greater accumulation of EPA and DHA in blood lipid pools.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Research shows that fish oil and its component fatty acids EPA and DHA provide health benefits such as reducing the risk of cardiac death and lowering inflammation.
Yet a large portion of the population is not consuming the recommended amount of fish due to high cost, dietary restrictions such as vegetarianism/veganism, concerns about high levels of mercury, general dislike, and other factors.
Additionally, to meet the recommendations fish and fish oil production present sustainability challenges.
A potential alternative is to utilize EPA and DHA from algae.
These sustainable oils can be added to foods increasing the potential for fatty acids to counteract chronic disease and increasing access to general consumers.
Previously, our lab has developed, and optimized EPA and DHA fortified non-dairy plant milk beverages utilizing algae oil emulsions (food grade).
Up to 0.4% algae oil can be added to soymilk with limited changes to overall liking.
This study will compare the algae oil fortified soymilk to a commercial algae oil capsule containing the same base oil with the goal of demonstrating equivalent or greater accumulation of EPA and DHA in blood lipid pools.
Subjects will consume either one beverage or two capsules per day, containing equivalent amounts of EPA and DHA.
Blood will be taken at 4 time points throughout the 6 week study, every two weeks and analyzed for EPA and DHA in different lipid types.
Additionally, participants will complete a food frequency questionnaire to evaluate their normal diet, sensory evaluation (overall liking, and attribute evaluation) of the beverages, and daily symptom and intake logs to track consumption and any side effects.
Study Type
Interventional
Enrollment (Estimated)
24
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yael Vodovotz, PhD
- Phone Number: 614-247-7696
- Email: vodovotz.1@osu.edu
Study Contact Backup
- Name: Abigail Sommer, MS
- Phone Number: 317-508-7748
- Email: sommer.155@osu.edu
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Recruiting
- Ohio State University Comprehensive Cancer Center
-
Contact:
- Yael Vodovotz, PhD
- Phone Number: 614-247-7696
- Email: vodovotz.1@osu.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Body mass index between 18 and 30 kg/m2
Exclusion Criteria:
- Being pregnant or nursing
- Having anemia or a condition that influences the ability to donate blood safely
- Allergies to the beverage or pill ingredients
- Diabetes
- High triglycerides or cholesterol
- Coagulation disorder
- Anticoagulation therapy or any drug that affects blood clotting.
- Taking prescribed dietary omega-3 fatty acid medications including fish oil or algae oil within the last 3 months
- Taking non-prescribed dietary omega-3 fatty acid supplements within the last 3 months and not willing to discontinue taking them for the study period
- Taking lipid lowering medications such as statins
- Sensory impairments which affect ability to taste, smell, or see food products
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Algae Oil Fortified Soymilk
Subjects will drink 12 ounces of 0.4% algae oil-fortified soymilk
|
Flavored soymilk beverage fortified with 0.4% algae oil with both EPA and DHA
|
Active Comparator: Algae Oil Supplements
Subjects will take 2 commercial algae oil capsules.
|
Algae oil capsules with EPA and DHA
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Erythrocyte EPA and DHA levels
Time Frame: 4 weeks
|
Percent EPA and DHA of total fatty acids in erythrocyte samples
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma EPA and DHA levels
Time Frame: 4 weeks
|
Percent EPA and DHA of total fatty acids in plasma samples
|
4 weeks
|
Peripheral blood mononuclear cell (PBMC) EPA and DHA levels
Time Frame: 4 weeks
|
Percent EPA and DHA of total fatty acids in PBMC samples
|
4 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compliance
Time Frame: 4 weeks
|
Percent of days that participants consume their beverage or pill
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Yael Vodovotz, PhD, Ohio State University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 3, 2023
Primary Completion (Estimated)
July 10, 2024
Study Completion (Estimated)
July 10, 2024
Study Registration Dates
First Submitted
March 22, 2023
First Submitted That Met QC Criteria
April 4, 2023
First Posted (Actual)
April 7, 2023
Study Record Updates
Last Update Posted (Estimated)
January 23, 2024
Last Update Submitted That Met QC Criteria
January 22, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- OSU-87
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Diet
-
University of ReadingActive, not recruitingDiet Modification | Diet, Healthy | Diet HabitUnited Kingdom
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
Washington State UniversityUnited States Department of Agriculture (USDA)Not yet recruitingHealth Behavior | Diet, Healthy | Diet HabitUnited States
-
University of HawaiiPennington Biomedical Research Center; United States Department of Agriculture...RecruitingDiet, HealthyUnited States
-
Harokopio UniversityRecruiting
-
Universitas Katolik Widya Mandala SurabayaNot yet recruitingDiet, HealthyIndonesia
-
Purdue UniversityMushroom CouncilCompleted
-
University of PalermoCompleted
-
Amazentis SACompleted
Clinical Trials on Algae Oil Fortified Soymilk
-
University of New MexicoNational Center for Research Resources (NCRR)TerminatedPregnancy | Randomized Clinical Trial | Docosahexaenoic AcidUnited States
-
Queen Fabiola Children's University HospitalTerminatedCongenital Heart Disease in ChildrenBelgium
-
Tufts UniversityWashington University School of Medicine; United States Agency for International... and other collaboratorsTerminated
-
National Nutrition and Food Technology InstituteCompletedHealthyIran, Islamic Republic of
-
Medecins Sans Frontieres, NetherlandsLondon School of Hygiene and Tropical Medicine; United Nations World Food Programme... and other collaboratorsCompletedModerate Acute MalnutritionSierra Leone
-
USDA, Western Human Nutrition Research CenterHarvestPlusCompleted
-
The Hospital for Sick ChildrenCompletedChild Nutrition DisordersCanada, Ethiopia
-
National Nutrition and Food Technology InstituteRecruitingDiabetesIran, Islamic Republic of